Immunocore Holdings PLC
IMCR36.130USD
-0.440-1.20%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.80BMarket Cap
LossP/E TTM
More Details of Immunocore Holdings PLC Company
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Immunocore Holdings PLC Info
Ticker SymbolIMCR
Company nameImmunocore Holdings PLC
IPO dateFeb 05, 2021
CEOJallal (Bahija)
Number of employees493
Security typeDepository Receipt
Fiscal year-endFeb 05
Address92 Park Drive Milton Park
CityABINGDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeOX14 4RY
Phone441235438600
Websitehttps://www.immunocore.com/
Ticker SymbolIMCR
IPO dateFeb 05, 2021
CEOJallal (Bahija)
Company Executives of Immunocore Holdings PLC
Name
Name/Position
Position
Shareholding
Change
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Berman, M.D., Ph.D.
Dr. David Berman, M.D., Ph.D.
Head of Research and Development
Head of Research and Development
--
--
Mr. Travis Coy
Mr. Travis Coy
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
--
--
Name
Name/Position
Position
Shareholding
Change
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
14.19%
RTW Investments L.P.
9.78%
Wellington Management Company, LLP
9.60%
Fidelity Management & Research Company LLC
8.81%
PRIMECAP Management Company
7.54%
Other
50.08%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
14.19%
RTW Investments L.P.
9.78%
Wellington Management Company, LLP
9.60%
Fidelity Management & Research Company LLC
8.81%
PRIMECAP Management Company
7.54%
Other
50.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.18%
Hedge Fund
28.59%
Investment Advisor/Hedge Fund
24.53%
Venture Capital
1.71%
Research Firm
1.62%
Private Equity
0.77%
Pension Fund
0.56%
Bank and Trust
0.07%
Family Office
0.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
300
49.40M
99.22%
-6.80M
2025Q2
293
49.19M
99.31%
-10.02M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
2023Q2
236
43.68M
94.12%
-435.38K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
7.07M
14.03%
+15.84K
+0.22%
Jun 30, 2025
RTW Investments L.P.
4.87M
9.66%
--
--
Jun 30, 2025
Wellington Management Company, LLP
5.13M
10.19%
+919.32K
+21.82%
Jul 31, 2025
Fidelity Management & Research Company LLC
4.82M
9.57%
+15.08K
+0.31%
Jun 30, 2025
PRIMECAP Management Company
3.77M
7.49%
+1.09M
+40.80%
Jun 30, 2025
Bellevue Asset Management AG
2.44M
4.85%
+1.22M
+99.86%
Jun 30, 2025
Tang Capital Management, LLC
2.11M
4.18%
+189.90K
+9.91%
Jun 30, 2025
Baker Bros. Advisors LP
2.32M
4.61%
--
--
Jun 30, 2025
Deep Track Capital LP
1.80M
3.57%
+388.60K
+27.53%
Jun 30, 2025
BVF Partners L.P.
1.02M
2.03%
+1.02M
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.49%
Tema Oncology ETF
1.11%
ALPS Medical Breakthroughs ETF
0.7%
ProShares Ultra Nasdaq Biotechnology
0.19%
SPDR S&P International Small Cap ETF
0.17%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Intl Small Cap Equity Factor ETF
0.12%
iShares Biotechnology ETF
0.1%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.49%
Tema Oncology ETF
Proportion1.11%
ALPS Medical Breakthroughs ETF
Proportion0.7%
ProShares Ultra Nasdaq Biotechnology
Proportion0.19%
SPDR S&P International Small Cap ETF
Proportion0.17%
Invesco Nasdaq Biotechnology ETF
Proportion0.13%
iShares Intl Small Cap Equity Factor ETF
Proportion0.12%
iShares Biotechnology ETF
Proportion0.1%
SPDR Portfolio Developed World ex-US ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immunocore Holdings PLC?
The top five shareholders of Immunocore Holdings PLC are:
T. Rowe Price Investment Management, Inc. holds 7.07M shares, accounting for 14.03% of the total shares.
RTW Investments L.P. holds 4.87M shares, accounting for 9.66% of the total shares.
Wellington Management Company, LLP holds 5.13M shares, accounting for 10.19% of the total shares.
Fidelity Management & Research Company LLC holds 4.82M shares, accounting for 9.57% of the total shares.
PRIMECAP Management Company holds 3.77M shares, accounting for 7.49% of the total shares.
T. Rowe Price Investment Management, Inc. holds 7.07M shares, accounting for 14.03% of the total shares.
RTW Investments L.P. holds 4.87M shares, accounting for 9.66% of the total shares.
Wellington Management Company, LLP holds 5.13M shares, accounting for 10.19% of the total shares.
Fidelity Management & Research Company LLC holds 4.82M shares, accounting for 9.57% of the total shares.
PRIMECAP Management Company holds 3.77M shares, accounting for 7.49% of the total shares.
What are the top three shareholder types of Immunocore Holdings PLC?
The top three shareholder types of Immunocore Holdings PLC are:
T. Rowe Price Investment Management, Inc.
RTW Investments L.P.
Wellington Management Company, LLP
T. Rowe Price Investment Management, Inc.
RTW Investments L.P.
Wellington Management Company, LLP
How many institutions hold shares of Immunocore Holdings PLC (IMCR)?
As of 2025Q3, 300 institutions hold shares of Immunocore Holdings PLC, with a combined market value of approximately 49.40M, accounting for 99.22% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.09%.
What is the biggest source of revenue for Immunocore Holdings PLC?
In FY2024, the -- business generated the highest revenue for Immunocore Holdings PLC, amounting to -- and accounting for --% of total revenue.
